Does Rallies show Form 4 insider transactions for KALA?

Yes. Rallies tracks KALA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KALA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KALA. It does not provide personalized investment advice.

KALA (KALA BIO, Inc. Common Stock) Stock Analysis - Insider Trades

KALA BIO, Inc. Common Stock (KALA) is a publicly traded Healthcare sector company. As of May 21, 2026, KALA trades at $2.65 with a market cap of $50.38M and a P/E ratio of -0.82. KALA moved +4.35% today. Year to date, KALA is -91.40%; over the trailing twelve months it is -98.66%. Its 52-week range spans $2.52 to $1,030.00. Rallies surfaces KALA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KALA stock inside the company?

Recent KALA insider activity includes Iwicki Mark T sold 154.89K, Reumuth Mary sold 967, Reumuth Mary sold 32.23K, Bazemore Todd sold 47.77K, and Brazzell Romulus K sold 46.75K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KALA Key Metrics

Key financial metrics for KALA
Metric	Value
Price	$2.65
Market Cap	$50.38M
P/E Ratio	-0.82
EPS	$-3.31
Dividend Yield	0.00%
52-Week High	$1,030.00
52-Week Low	$2.52
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-26.98M
Gross Margin	0.00%

Recent KALA Insider Trades

Iwicki Mark T sold 154.89K (~$125.46K) on Oct 23, 2025.
Reumuth Mary sold 967 (~$792.94) on Oct 23, 2025.
Reumuth Mary sold 32.23K (~$26.75K) on Oct 22, 2025.
Bazemore Todd sold 47.77K (~$39.65K) on Oct 22, 2025.
Brazzell Romulus K sold 46.75K (~$38.80K) on Oct 22, 2025.

Latest KALA News

Kala Bio Initiates 1-for-50 Reverse Split, Reduces Shares Outstanding to 18.6M — May 7, 2026
Trump Executive Order Allocates $50M to Psychedelic Research Boosting Kala Bio’s AI Platform — Apr 21, 2026
Kala Bio Deploys Bionic Intelligence Agent for Biotech with 70B-Parameter AI Model — Mar 30, 2026
Kala Bio to Ship First AI Agent in 14 Days, Tackles $180B Healthcare AI Market — Mar 11, 2026
KALA BIO Secures Exclusive License to Younet AI's Researgency Platform — Mar 9, 2026

KALA Analyst Consensus

KALA analyst coverage data. Average price target: $0.00.

Common questions about KALA

Who is trading KALA stock inside the company?: Recent KALA insider activity includes Iwicki Mark T sold 154.89K, Reumuth Mary sold 967, Reumuth Mary sold 32.23K, Bazemore Todd sold 47.77K, and Brazzell Romulus K sold 46.75K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KALA?: Yes. Rallies tracks KALA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KALA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KALA. It does not provide personalized investment advice.